# Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease

> **NCT06982079** · PHASE3 · RECRUITING · sponsor: **Ain Shams University** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Kidney Disease Stage 5
- CKD Stage 4

## Interventions

- **DRUG:** Dapagliflozin 10 mg

## Key facts

- **NCT ID:** NCT06982079
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982079, "Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06982079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*